NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
11/03/2026
Voltar para busca
Dado oficial do USPTO
VIVLION
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
44
Atualização mais recente
12/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
03/07/2018
Data de registro
12/11/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/03/2026
Última transação
12/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
701
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
16
Localização do titular
FRANKFURT AM MAIN, DE
Examinador
KUMIS, SCOTT N
Localização atual
Historical data usage
Titulares e representantes
Titulares
VIVLION GMBH
D. K. (pessoa física)
Representantes
Daniel A. Grossman ZVMLaw PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Reagents for scientific use; chemical preparations for scientific and research purposes; biological preparations for scientific research purposes; biochemical products for scientific use in vivo and in vitro
Classe 5
Biological preparations for the treatment of cancerneurodegenerationimmunologic diseasescardiovascular diseasesmetabolic diseasesinfectionsmental diseases and respiratory diseases for medical purposes; biochemical preparations for the treatment of cancerneurodegenerationimmunologic diseasescardiovascular diseasesmetabolic diseasesinfectionsmental diseases and respiratory diseases for medical purposes; chemical reagents for medical purposes; biotechnological preparations for the treatment of cancerneurodegenerationimmunologic diseasescardiovascular diseasesmetabolic diseasesinfectionsmental diseases and respiratory diseases for medical purposes; diagnostic agentspreparations and substances for medical purposes; diagnostic reagents for medical purposes; nucleic acid sequences for medical purposes; pharmaceutical preparationstherapeutic medicines and substances for the treatment of cancerneurodegenerationimmunologic diseasescardiovascular diseasesmetabolic diseasesinfectionsmental diseases and respiratory diseases; nucleoside-containing pharmaceutical preparationsantivirals for scientific biomedical purposes
Classe 42
Research and development services for the pharmaceutical industry; research and development services for the biotechnology sector; scientific researchtesting and analysis services in the field of pharmaceuticals; laboratory research services in the field of pharmaceuticals; advisory services relating to technical and scientific analysis of pharmaceuticals; technical and scientific analysis in the field of pharmaceuticals; biomedical research; pharmaceutical research and development; scientific research for medical purposes; scientific research in the nature of analysis of large datasets relating to data connectivitytargeted data search; Provision of information and data relating to medical and veterinary research and development in the field of pharmaceuticals; Provision of information and data relating to scientific and technological research and development in the field of pharmaceuticals; computer aided scientific research analysis; Provision of online scientific information for industrial analysis and research in the field of pharmaceuticals; preparation of biological samples for scientific testing and analysis in research laboratories
Publicações
Histórico de despachos e eventos da marca no USPTO.
44 publicações encontradas
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
11/03/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/03/2026
ES8R
TEAS SECTION 8 RECEIVED
21/10/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/11/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
20/09/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
20/09/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
20/09/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
20/09/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
20/09/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
20/09/2024
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
20/09/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
29/01/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
12/11/2019
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
04/10/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/10/2019
IUCN
NOTICE OF ALLOWANCE CANCELLED
27/08/2019
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
27/08/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/08/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/08/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
16/04/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/02/2019
PUBO
PUBLISHED FOR OPPOSITION
19/02/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/01/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/01/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
15/01/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
15/01/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
15/01/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
15/01/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/12/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/12/2018
ALIE
ASSIGNED TO LIE
12/12/2018
DOCK
ASSIGNED TO EXAMINER
11/12/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/12/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/11/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/11/2018
ALIE
ASSIGNED TO LIE
21/11/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/11/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/10/2018
GNRT
NON-FINAL ACTION E-MAILED
24/10/2018
CNRT
NON-FINAL ACTION WRITTEN
24/10/2018
DOCK
ASSIGNED TO EXAMINER
24/10/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/07/2018
NWAP
NEW APPLICATION ENTERED
06/07/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VIVLION ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.